NMRA net incomeQ2 2026-$43.08M
NMRA net income was -$43.08M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$52.73M a year earlier. For the full fiscal 2025 it was -$236.93M, compared with -$243.79M in fiscal 2024.
Neumora Therapeutics Inc. (NMRA) financials
For the twelve months ended Jun 30, 2026, Neumora Therapeutics Inc. reported -$212.75M of net income.
- Net income, TTM
- -$212.75M
- EPS, diluted, TTM
- -$1.23
- Cash
- $116.83M
- Total debt
- $112.91M
- Market cap
- $87.6M
FY2022FY2025
FY2022FY2023
NMRA revenue and earnings growth
NMRA EPSQ2 2026-$0.23
NMRA diluted EPS was -$0.23 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.33 a year earlier. For the full fiscal 2025 it was -$1.45, compared with -$1.53 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Research and development | $176.06M | $200.93M | $142.72M | $91.75M |
| Selling, general and admin | $60.09M | $62.54M | $45.48M | $31.12M |
| Operating income | -$241.16M | -$263.46M | -$252.10M | -$135.87M |
| Interest expense | $2.01M | $0 | - | - |
| Pre-tax income | -$236.80M | -$243.61M | -$235.66M | -$130.90M |
| Income tax | $130.0K | $178.0K | $268.0K | - |
| Net income | -$236.93M | -$243.79M | -$235.93M | -$130.90M |
| EPS, basic | -$1.45 | -$1.53 | -$3.63 | -$4.81 |
| EPS, diluted | -$1.45 | -$1.53 | -$3.63 | -$4.81 |
| Diluted shares | 163.4M | 159.4M | 65.0M | 27.2M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $182.53M | $142.15M | $374.04M | $240.94M |
| Short-term investments | - | $165.43M | $79.94M | $130.94M |
| Current assets | $190.54M | $314.06M | $478.28M | $387.95M |
| Total assets | $191.05M | $316.97M | $496.19M | $426.23M |
| Current liabilities | $32.45M | $29.89M | $25.11M | $23.70M |
| Short-term debt | $60.00M | - | - | - |
| Long-term debt | $54.53M | $0 | - | - |
| Total debt | $114.53M | $0 | - | - |
| Total liabilities | $87.18M | $29.91M | $27.12M | $29.40M |
| Shareholders' equity | $103.87M | $287.06M | $469.08M | -$446.85M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$206.44M | -$182.94M | -$163.28M | -$114.90M |
| Capital expenditures | - | - | $117.0K | $511.0K |
| Free cash flow | - | - | -$163.40M | -$115.41M |
| Investing cash flow | $168.52M | -$70.56M | $64.39M | -$168.01M |
| Financing cash flow | $77.09M | $21.60M | $231.94M | $115.74M |
| Stock-based compensation | $29.88M | $39.99M | $17.24M | $8.30M |
| Depreciation and amortization | $208.0K | $631.0K | $668.0K | $594.0K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $29.28M | $38.60M | $44.67M | $40.52M | $38.72M | $52.15M | $45.91M | $60.63M | $48.63M | $45.76M | $38.86M | $41.60M |
| Selling, general and admin | $12.91M | $14.27M | $13.81M | $12.18M | $15.32M | $18.79M | $17.01M | $16.02M | $15.19M | $14.32M | $11.24M | $15.26M |
| Operating income | -$42.19M | -$52.86M | -$58.48M | -$57.70M | -$54.04M | -$70.94M | -$62.92M | -$76.65M | -$63.82M | -$60.07M | -$114.00M | -$56.86M |
| Interest expense | $1.43M | $1.44M | $827.0K | $747.0K | $307.0K | $0 | $0 | $0 | - | - | - | - |
| Pre-tax income | -$43.08M | -$53.43M | -$59.45M | -$56.76M | -$52.71M | -$67.89M | -$58.82M | -$72.49M | -$58.58M | -$53.72M | -$108.46M | -$53.03M |
| Income tax | $0 | $30.0K | $0 | $0 | $25.0K | $105.0K | $0 | $53.0K | $125.0K | $0 | - | - |
| Net income | -$43.08M | -$53.46M | -$59.45M | -$56.76M | -$52.73M | -$67.99M | -$58.82M | -$72.55M | -$58.70M | -$53.72M | -$108.73M | -$53.03M |
| EPS, basic | -$0.23 | -$0.30 | -$0.35 | -$0.35 | -$0.33 | -$0.42 | -$0.37 | -$0.45 | -$0.37 | -$0.34 | - | -$1.14 |
| EPS, diluted | -$0.23 | -$0.30 | -$0.35 | -$0.35 | -$0.33 | -$0.42 | -$0.37 | -$0.45 | -$0.37 | -$0.34 | - | -$1.14 |
| Diluted shares | 185.2M | 179.9M | - | 161.8M | 161.7M | 161.5M | - | 159.6M | 159.0M | 157.9M | - | 46.7M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $116.83M | $147.07M | $182.53M | $129.07M | $124.52M | $126.86M | $142.15M | $275.71M | $150.68M | $182.93M | $374.04M | $412.28M |
| Short-term investments | - | - | - | $42.45M | $93.06M | $122.49M | $165.43M | $65.59M | $220.96M | $239.79M | $79.94M | $97.28M |
| Current assets | $124.87M | $153.43M | $190.54M | $177.08M | $222.91M | $254.87M | $314.06M | $348.61M | $398.32M | $442.79M | $478.28M | $525.74M |
| Total assets | $125.25M | $153.88M | $191.05M | $177.83M | $223.82M | $256.75M | $316.97M | $352.54M | $404.47M | $450.21M | $496.19M | $544.75M |
| Current liabilities | $27.78M | $30.11M | $32.45M | $25.84M | $21.16M | $28.38M | $29.89M | $31.74M | $23.13M | $24.61M | $25.11M | $29.12M |
| Short-term debt | $60.00M | $60.00M | $60.00M | $20.00M | $20.00M | - | - | - | - | - | - | - |
| Long-term debt | $52.91M | $52.96M | $54.53M | $19.56M | $19.45M | - | $0 | - | - | - | - | - |
| Total debt | $112.91M | $112.96M | $114.53M | $39.56M | $39.45M | - | $0 | - | - | - | - | - |
| Total liabilities | $80.73M | $83.20M | $87.18M | $45.67M | $40.95M | $28.38M | $29.91M | $31.80M | $23.21M | $25.67M | $27.12M | $32.06M |
| Shareholders' equity | $44.52M | $70.68M | $103.87M | $132.16M | $182.88M | $228.36M | $287.06M | $320.74M | $381.26M | $424.54M | $469.08M | $512.69M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39.53M | -$46.40M | -$47.95M | -$46.63M | -$52.40M | -$59.45M | -$50.34M | -$33.48M | -$56.16M | -$42.95M | -$51.44M | -$47.77M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | - | $44.0K | $37.0K |
| Free cash flow | - | - | - | - | - | - | - | - | - | - | -$51.49M | -$47.81M |
| Investing cash flow | $0 | $71.0K | $42.65M | $51.32M | $30.40M | $44.16M | -$98.80M | $156.99M | $21.25M | -$150.00M | $13.68M | $23.82M |
| Financing cash flow | $9.29M | $10.88M | $58.77M | -$136.0K | $18.46M | $0 | $15.57M | $1.53M | $2.65M | $1.84M | -$481.0K | $232.02M |
| Stock-based compensation | $7.18M | $7.41M | $7.41M | $5.98M | $7.17M | $9.32M | $9.90M | $9.95M | $12.77M | $7.37M | $6.05M | $6.45M |
| Depreciation and amortization | $7.0K | $8.0K | $9.0K | $23.0K | $19.0K | $157.0K | $157.0K | $156.0K | $160.0K | $158.0K | $166.0K | $173.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 4.50 | 5.09 | 5.87 | 6.85 | 10.54 | 8.98 | 10.51 | 10.98 | 17.22 | 17.99 | 19.05 | 18.05 |
| Debt to equity | 2.54 | 1.60 | 1.10 | 0.30 | 0.22 | - | 0.00 | - | - | - | - | - |
Source: XBRL data Neumora Therapeutics Inc. files with the SEC, latest filing dated Aug 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
NMRA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| NMRA | - | - | -$212.75M | - | $87.6M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $211.94B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.49B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $60.30B |
| RVMD | $0 | - | -$1.13B | - | $41.76B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.44B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.91B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.22B |
NMRA FAQ
5 questionsIs NMRA profitable?
No. Neumora Therapeutics Inc. reported a net loss of $212.75M for the twelve months ended Jun 30, 2026.How much cash and debt does NMRA have?
Neumora Therapeutics Inc. reported $116.83M in cash and cash equivalents and $112.91M of debt on its most recent balance sheet in SEC filings.What is NMRA earnings per share?
Diluted earnings per share were -$1.23 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did NMRA last report financial results?
The latest statements here come from Neumora Therapeutics Inc.'s 10-Q filed on Aug 14, 2026, covering the period ended Jun 30, 2026.Where does this NMRA financial data come from?
Quantisnow builds these statements from the structured XBRL data Neumora Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.